Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972278 · ClinicalTrials.gov registry record · Phase 1
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
A Phase 1 study of Lipid Metabolism, sponsored by NewAmsterdam Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05972278 is a Phase 1 study of Lipid Metabolism that is active but no longer recruiting, run by NewAmsterdam Pharma. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05972278, a Phase 1 study of Lipid Metabolism, is active but no longer recruiting, sponsored by NewAmsterdam Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Conditions Studied
Interventions
- DRUG Obicetrapib
Study Locations (1)
Pennsylvania
- Archna Bajaj, MD - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05972278
The ClinicalTrials.gov registry entry for NCT05972278 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipid Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Obicetrapib is the first listed.
NCT05972278 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05972278 about?
NCT05972278 is a clinical study titled "Investigating the Effect of Obicetrapib on Lipoprotein Metabolism". To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
What is the current status of trial NCT05972278?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-12-01. Estimated completion is 2024-10-14.
What conditions does trial NCT05972278 study?
This clinical trial studies the following conditions: Lipid Metabolism.
What interventions are being tested in trial NCT05972278?
The interventions under investigation include: Obicetrapib (DRUG).
Who is sponsoring clinical trial NCT05972278?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972278 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipid Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.